Covaprendo 5/5 mg - 30 Tablet

Angiotensin-converting enzyme inhibitor and calcium channel blocker combination therapy used in the treatment of hypertension.

Administer with or without food.

-Side effects due to amlodipine: Peripheral edema, flushing, palpitations, pruritus , skin rash, abdominal pain, nausea, dizziness, drowsiness, fatigue, male sexual disorder, asthenia, muscle cramps, dyspnea, peripheral ischemia, sinus tachycardia, syncope, vasculitis, diaphoresis, erythema multiforme, hot flash, hyperglycemia, weight gain, weight loss, anorexia, constipation, dysphagia, flatulence, gingival hyperplasia, pancreatitis, vomiting, xerostomia, difficulty in micturition, nocturia, urinary frequency, leukopenia, purpuric disease, thrombocytopenia, angioedema, hypersensitivity reaction, abnormal dreams, anxiety, depersonalization, depression, female sexual disorder, hypoesthesia, insomnia, malaise, pain, paresthesia, peripheral neuropathy, rigors, vertigo, arthralgia, back pain, myalgia, osteoarthritis, tremor, conjunctivitis, diplopia, eye pain, tinnitus and epistaxis. -Side effects due to perindopril: Headache, cough, edema, chest pain, ECG abnormality, palpitations, hypertonia, sleep disorder, depression, paresthesia, drowsiness, nervousness, skin rash, increased serum triglycerides, menstrual disease, diarrhea, abdominal pain, dyspepsia, nausea, vomiting, flatulence, urinary tract infection, proteinuria, sexual disorder, increased serum ALT, seasonal allergy, weakness, back pain , leg pain, arm pain, arthralgia, arthritis, myalgia, neck pain, tinnitus, otic infection, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis and fever.

-Should not be given to patients suffering from hypersensitivity to perindopril or amlodipine. -A rare toxicity associated with ACE inhibitors includes cholestatic jaundice. -ACE inhibitor may cause dry cough. -ACE inhibitors may cause hyperkalemia. -ACE inhibitors may cause hypotension. -Perindopril may be associated with deterioration of renal function and/or increases in BUN and serum creatinine, particularly in patients with low renal blood flow. -Use with extreme caution in patients with severe aortic stenosis. -Use perindopril with caution in patients with collagen vascular disease especially with concomitant renal impairment. -Use with caution in patients with hepatic impairment. -Use with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction. -Use perindopril with caution in patients with unstented unilateral or bilateral renal artery stenosis. -In case of over dose be ready to tell or show what was taken, how much and when it happened, and seek immediate medical attention. For additional information call us on 16676. Always tell your physician your detailed medical history.

Store at room temperature.

Interactions due to amlodipine: -Alfuzosin: May enhance the hypotensive effect of blood pressure lowering agents. -Antipsychotic Agents: blood pressure lowering agents may enhance the hypotensive effect of antipsychotic agents. -Calcium Salts: May diminish the therapeutic effect of calcium channel blockers. -Carbamazepine: amlodipine may increase the serum concentration of carbamazepine. -Clopidogrel: Calcium channel blockers may diminish the therapeutic effect of Clopidogrel. -Dapoxetine: May enhance the orthostatic hypotensive effect of calcium channel blockers. -Lovastatin: Amlodipine may increase the serum concentration of Lovastatin. -Melatonin: May diminish the antihypertensive effect of calcium channel blockers. -Simvastatin: Amlodipine may increase the serum concentration of Simvastatin. Interactions due to perindopril: -Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. -Azathioprine: ACE Inhibitors may enhance the myelosuppressive effect of Azathioprine. -Duloxetine: ACE inhibitors may enhance the hypotensive effect of Duloxetine. -Ferric Hydroxide Polymaltose Complex: ACE inhibitors may enhance the adverse/toxic effect of Ferric Hydroxide Polymaltose Complex. -Iron Dextran Complex: ACE inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. -Levodopa-containing products: ACE inhibitors may enhance the hypotensive effect of Levodopa-containing products. -NSAID: ACE inhibitors may enhance the adverse/toxic effect of NSAID. -Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of ACE inhibitors. -Potassium Salts: May enhance the hyperkalemic effect of ACE inhibitors. -Pregabalin: Angiotensin-converting enzyme inhibitors may enhance the adverse/toxic effect of Pregabalin. -Tizanidine: May enhance the hypotensive effect of angiotensin-converting enzyme inhibitors. -Trimethoprim: May enhance the hyperkalemic effect of angiotensin-converting enzyme inhibitors.

-Drugs that act directly on the renin-angiotensin system can cause injury to the developing fetus. -Amlodipine is present in breast milk; it is not known if perindopril is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, it is recommended to discontinue breastfeeding or discontinue therapy. -Ask your physician before taking any medication during pregnancy or lactation.

GLOBAL NAPI PHARMACEUTICALS